Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.
about
HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations.A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection.Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.Quantitation of human immunodeficiency virus type 1 (HIV-1) RNA in cell-free cervicovaginal secretions: comparison of reverse transcription-PCR amplification (AMPLICOR HIV-A MONITOR 1.5) with enhanced-sensitivity branched-DNA assay (Quantiplex 3.0)Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women.Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.Treatment to prevent transmission of HIV-1Study of compartmentalization in the visna clinical form of small ruminant lentivirus infection in sheep.Ontogeny and specificities of mucosal and blood human immunodeficiency virus type 1-specific CD8(+) cytotoxic T lymphocytes.Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.Comparison of washing and swabbing procedures for collecting genital fluids to assess shedding of human immunodeficiency virus type 1 (HIV-1) RNA in asymptomatic HIV-1-infected women.Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)Comparison of washing and swabbing procedures for collecting genital fluids to assess cervicovaginal shedding of herpes simplex virus type 2 DNA.Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapyImmunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1.German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs.Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.HIV migration between blood plasma and cellular subsets before and after HIV therapy.Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time.Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.Small ruminant lentiviruses: genetic variability, tropism and diagnosis.Novel methodology for antiretroviral quantitation in the female genital tractGenital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets.Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses.Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.
P2860
Q28541918-7E76B5A2-E74F-4398-B8B6-8833EA67E957Q33505667-332FFC05-2F1E-4D53-8EE9-C6FF2A269B1FQ33728690-2211DA1D-6F16-422B-A9C9-7B585BD3F926Q33779372-B2CA43D5-C796-4FB7-B5A8-834DA9D6B1FDQ33821263-2113CE8E-95AE-4E19-B3E5-AB0822DA2A16Q33972457-48A153A3-5979-4969-802F-095738D63A67Q33999468-00DF045B-0F32-407A-9A04-62D7718123CFQ34028490-31F5932C-D271-4359-AAF5-9DAB7731A6CBQ34102424-A8D2A8BF-728F-457F-931F-9280854FEA48Q34142442-8D5E2142-519F-4E0E-8788-E4055A3DC9F7Q34461798-9108FED6-441B-4ADA-9B17-1A590D2D3080Q34725556-86D9E98A-7E0B-43E0-88EB-4D545993EE6CQ34746846-4D5F8275-44EA-4CD9-BA33-26D76875F8CAQ34995949-117F1D20-887D-4BDD-AE02-2F28E9D82768Q35005146-F95E30FE-A4D0-49CC-8639-14F544F9E0D1Q35026748-5EE57367-8979-4B2B-9503-DADD77758DEFQ35077988-AF3E44FA-BE04-4748-BE9C-4180315A6B3CQ35102123-5CCC4DCD-865E-458D-BB31-326E67117E48Q35219574-3F6062F6-2481-4830-AF1C-17431ACE8341Q35547967-840465AE-1A2C-480C-965A-0C7FCC2F7804Q35742512-5081BAA9-352A-432A-BD21-585C7B5A6223Q35857191-4090B287-4471-47C6-ADF4-BF3A8B69981DQ35960319-E96D33E3-79AE-412F-8FE8-AD057EEA6B93Q36086387-C2F05FD7-8CC0-4B1A-BA11-CCD682DC23E3Q36109214-9AF054C3-D030-44BE-9E2E-07CCAD212103Q36430073-79DE0B7C-4EA9-4F07-8C54-075181D3A999Q36515298-DDBC543D-296B-4201-B041-5869B1D09B67Q36702615-5E44AE08-877C-4167-8231-211C6E837F37Q36891072-D343630B-EA22-47C6-A8D9-6705BD789978Q36993859-7CBD5C03-DF78-4D8D-BE16-C050ADF8C336Q37158604-F7195DAC-0529-4023-9F4E-D447BE18F1E2Q37204271-FD83EC6D-A1A6-4913-83ED-A6DEA2F0BA38Q37362444-A003B921-2879-48C4-BF18-E2BCB27623EBQ37366730-AB408797-052E-4CCC-B198-415180B94BE3Q43564279-AE0811DC-8502-48DA-9523-3E3553BA3B7AQ43871660-8E1F57BE-C5E4-42B4-A063-00D2AEF1B606Q46791174-A7A11A82-D83A-4307-8916-229B50DF146E
P2860
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Selection of drug-resistant va ...... eiving antiretroviral therapy.
@en
Selection of drug-resistant va ...... eiving antiretroviral therapy.
@nl
type
label
Selection of drug-resistant va ...... eiving antiretroviral therapy.
@en
Selection of drug-resistant va ...... eiving antiretroviral therapy.
@nl
prefLabel
Selection of drug-resistant va ...... eiving antiretroviral therapy.
@en
Selection of drug-resistant va ...... eiving antiretroviral therapy.
@nl
P2093
P356
P1476
Selection of drug-resistant va ...... eiving antiretroviral therapy.
@en
P2093
Bernard MC
Kazatchkine MD
P304
P356
10.1086/315679
P407
P577
2000-07-06T00:00:00Z